YAP1 and hepatocellular carcinoma: A previous study has proven that combining a YAP inhibitor (Verteporfin) with chemotherapeutic agents (5-fluorouracil, doxorubicin) has effectively overcome chemoresistance in HCC cell lines (BEL/FU) and in vivo [17].